NYSE:SYK - Stryker Stock Price, Forecast & News

Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."

Stryker announced a quarterly dividend on Friday, February 7th. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.575 per share on Thursday, April 30th. This represents a $2.30 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date of this dividend is Monday, March 30th. View Stryker's Dividend History.

Stryker Co. (NYSE:SYK) posted its earnings results on Tuesday, January, 28th. The medical technology company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.46 by $0.03. The medical technology company had revenue of $4.13 billion for the quarter, compared to analyst estimates of $4.11 billion. Stryker's revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.18 earnings per share. View Stryker's Earnings History.

Stryker is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Stryker.

Stryker updated its FY20 earnings guidance on Tuesday, January, 28th. The company provided earnings per share guidance of $9.00-9.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.04.

22 brokerages have issued 12 month price targets for Stryker's shares. Their forecasts range from $192.00 to $250.00. On average, they anticipate Stryker's share price to reach $229.10 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price. View Analyst Price Targets for Stryker.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.

Headlines about SYK stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Stryker earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the medical technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Stryker.

Stryker saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,910,000 shares, an increase of 10.8% from the December 31st total of 3,530,000 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 2.9 days. Currently, 1.1% of the company's shares are sold short. View Stryker's Current Options Chain.

Some companies that are related to Stryker include Abbott Laboratories (ABT), ABIOMED (ABMD), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX) and Cardiovascular Systems (CSII).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stryker investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Home Depot (HD), Visa (V), AbbVie (ABBV), Boeing (BA), Medtronic (MDT), NVIDIA (NVDA), Abbott Laboratories (ABT) and CVS Health (CVS).

Stryker's stock is owned by a number of of retail and institutional investors. Top institutional investors include Greenleaf Trust (5.74%), State Street Corp (3.66%), FMR LLC (2.91%), Bank of New York Mellon Corp (1.86%), Franklin Resources Inc. (1.52%) and Massachusetts Financial Services Co. MA (1.37%). Company insiders that own Stryker stock include Allan C Golston, Bijoy Sagar, David Floyd, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Institutional Ownership Trends for Stryker.

SYK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Massachusetts Financial Services Co. MA, Jensen Investment Management Inc., Amundi Pioneer Asset Management Inc., Retirement Systems of Alabama, DekaBank Deutsche Girozentrale, Sei Investments Co. and Railway Pension Investments Ltd. Company insiders that have sold Stryker company stock in the last year include Allan C Golston, Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.

SYK stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Point72 Asset Management L.P., CWS Financial Advisors LLC, PGGM Investments, State Street Corp, Schroder Investment Management Group, GQG Partners LLC and UBS Group AG. View Insider Buying and Selling for Stryker.

Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYK stock can currently be purchased for approximately $221.54.